Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 12/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 3/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26964494 | 1.00 | SLC40A1 (0.62) | SLC40A1MEN1AGTR1KMT2APOLB | |
| SCHEMBL26964389 | 0.92 | MEN1 (0.56) | SLC40A1MEN1AGTR1KMT2APOLB | |
| SCHEMBL30553417 | 0.92 | MEN1 (0.56) | SLC40A1MEN1AGTR1KMT2APOLB | |
| SCHEMBL30925426 | 0.86 | SLC40A1 (0.48) | SLC40A1MEN1AGTR1KMT2AALDH1A1 | |
| SCHEMBL27214204 | 0.85 | SLC40A1 (0.47) | SLC40A1MEN1KMT2A | |
| SCHEMBL26964180 | 0.82 | CKS1B (0.50) | SLC40A1GLO1 | |
| SCHEMBL30553433 | 0.82 | CKS1B (0.50) | SLC40A1GLO1 | |
| SCHEMBL26964597 | 0.82 | SLC40A1 (0.53) | SLC40A1MEN1KMT2ABRD4 | |
| SCHEMBL30925440 | 0.80 | GLO1 (0.56) | SLC40A1MEN1AGTR1KMT2AALDH1A1 | |
| SCHEMBL27214285 | 0.80 | GLO1 (0.56) | SLC40A1MEN1AGTR1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ZOETIS LLC | 2024-05-09 | — | — | US | disclosed |
| CN-116806218-A | Sulfonamide and its use for the treatment of parasitic helminth infections and diseases | 新基公司 | 2023-09-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ARSA, MRPS2, SULT2A1 | SLC40A1 3357/4885MEN1 2604/4885AGTR1 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.